Hong Kong SAR

Chinese teahouse chain Nayuki Holdings has set its Hong Kong IPO in motion, having dropped an earlier plan to list in the US.

Mainland China-listed Joinn Laboratories has begun bookbuilding for its up to HK$6.54bn ($843.9m) Hong Kong IPO, becoming one of the first companies to hit the equities market following the Chinese New Year break.

Hong Kong’s Securities and Futures Commission (SFC) is planning to bring in sweeping changes to rules governing equity and bond deals, requiring syndicate teams to be fixed earlier and fee structures to be disclosed. The moves have divided bankers. Jonathan Breen and Morgan Davis report.

New Horizon Health, a medical device manufacturer, has scooped up HK$2.04bn ($263.4m) from its IPO after strong institutional investor demand pushed pricing up to the top of the marketed range.

Nominative determinism has come up in Taipan before. But not everyone can love thy fate.

China Taiping Insurance Group Co has raised a HK$8.7bn ($1.12bn) loan to refinance debt taken for the acquisition of an office building in Hong Kong.

Hong Kong’s stock exchange operator has named Nicolas Aguzin, chief executive of JP Morgan’s international private bank, as its new CEO.

China-based Betta Pharmaceuticals, a developer of cancer treatments, is planning a Hong Kong IPO, having filed draft paperwork with the city’s stock exchange on Monday.

Hong Kong’s Securities and Futures Commission (SFC) is planning to introduce new rules that will require syndicate teams on bond and equity deals to be fixed earlier and brokers to disclose their fee structures, moves that are aimed at improving transparency in the city's capital markets and hold banks more accountable for their transactions.

Banks operating in Hong Kong are actively pushing for the adoption of alternative risk-free rates as the deadline for phasing out Libor, the old lending benchmark, approaches.

JP Morgan has named Simone Haslinger and Jonas Troeber as the co-heads of its equity capital markets business in Australia and New Zealand.

Medical device manufacturer New Horizon Health has pulled in early demand to cover its Hong Kong IPO multiple times over, according to a source familiar with the matter.